Mitochondrial cardiomyopathies

Article written and reviewed by Dr Luca Moretti

Mitochondrial cardiomyopathies are myocardial diseases caused by genetic defects in oxidative phosphorylation, mitochondrial translation, DNA maintenance, membranes or organelle dynamics. The heart derives most of its ATP from mitochondria and has little tolerance for a sustained deficit; it responds with hypertrophy, dilation, fibrosis and electrical instability. Energetic cardiomyopathy is often part of a multisystem disease, but it may also precede neurologic disease and myopathy by years.

There is no single mitochondrial gene: mitochondrial DNA encodes 37 elements, whereas more than a thousand proteins required by the organelle depend on the nuclear genome. mtDNA variants follow maternal inheritance and heteroplasmy phenomena; nuclear variants follow autosomal or X-linked inheritance. The same phenotype may therefore have different inheritance patterns, and the same variant may manifest with cardiac disease, diabetes, deafness or neurologic episodes in different combinations. Dual genomic control is the principle governing diagnosis and counseling.

Bioenergetics, heteroplasmy and threshold

The respiratory chain transfers electrons and creates a proton gradient used by ATP synthase. Defects of the complexes, coenzyme Q, tRNAs and ribosomes, or their assembly reduce ATP and increase reactive species; cardiolipin abnormalities, as in Barth syndrome, disrupt membranes. Calcium, pore opening and apoptosis add further injury. Reduced energy reserve may be adequate at rest and collapse during fever, tachycardia or fasting.

Heteroplasmy means the coexistence of mutated and non-mutated mtDNA molecules. During cell division and throughout life, their proportion is distributed differently among blood, muscle, heart and other organs; a tissue manifests disease when it exceeds a threshold that depends on the defect and metabolic demand. Therefore, the percentage in blood does not perfectly predict cardiac involvement and may decline with age for some variants. The tissue threshold explains maternally related family members with markedly different severity.

Large mtDNA deletions are often sporadic and cause syndromes such as Kearns-Sayre; point variants may be inherited, such as m.3243A>G associated with MELAS and maternally inherited diabetes and deafness, or m.8344A>G associated with MERRF. Nuclear genes include respiratory-chain proteins, tRNA synthetases, translation factors, mtDNA maintenance proteins and mitochondrial dynamics proteins. Molecular nomenclature is preferable to a syndromic acronym when the patient does not meet every classical feature.

Cardiac phenotypes and natural history

Hypertrophic cardiomyopathy is common in childhood and may be concentric, biventricular and non-obstructive; the dilated form may occur in isolation or after a hypertrophic phase. Noncompaction, mixed phenotypes and right ventricular dysfunction have been described. Increased wall thickness may represent a trophic response rather than storage and may change during a crisis. Phenotypic plasticity requires serial imaging and makes a classification assigned once insufficient.

Heart failure results from contractile impairment, abnormal relaxation, arrhythmias and the inability to increase ATP during exertion. Mild dysfunction may deteriorate rapidly during infection, anesthesia or fasting and recover only partially. In children, cardiomyopathy is an important prognostic indicator; in adults it may remain subclinical until diabetes, renal failure or hypertension reduce reserve. Stress vulnerability is part of the clinical definition.

Non-ischemic fibrosis on CMR and atrial remodeling create a substrate for tachyarrhythmias; conduction disease may be disproportionate to ventricular function. Some genotypes present mainly with heart block or pre-excitation, others with cardiomyopathy. No single measurement predicts all events, and the absence of hypertrophy does not exclude electrical risk. Independent electrical phenotyping should accompany echocardiography.

Syndromes with prominent cardiac involvement

MELAS is associated with stroke-like episodes, encephalopathy, seizures, lactic acidosis, hearing loss and often diabetes; m.3243A>G is the most common variant but not the only one. The heart may develop hypertrophy, dilation and arrhythmias even in maternal relatives without neurologic episodes. MERRF combines myoclonic epilepsy, ragged-red fibers, ataxia and myopathy with possible cardiac disease. The oligosymptomatic family may be where the cardiologist recognizes maternal inheritance.

Kearns-Sayre begins before the age of twenty with progressive external ophthalmoplegia, pigmentary retinopathy and systemic manifestations caused by a large mtDNA deletion. Atrioventricular block may progress unpredictably to complete block and sudden death; prophylactic pacing is considered at lower thresholds than in the general population. A pacemaker does not protect against ventricular tachyarrhythmias, so function, arrhythmias and scar guide device selection. The conduction threat requires close surveillance even without symptoms.

Barth syndrome is an X-linked disorder caused by TAFAZZIN variants and cardiolipin deficiency, with dilated or noncompaction cardiomyopathy, neutropenia, myopathy, poor growth and 3-methylglutaconic aciduria. The phenotype fluctuates and may improve after childhood, but infections and arrhythmias remain risks. Cardiolipin analysis and genetic testing confirm the diagnosis. The cardiohematologic signature distinguishes it from common infantile DCM.

mtDNA depletion syndromes and defects in TMEM70, AGK, FBXL4, ELAC2, AIFM1 and numerous translation genes may present with infantile cardiomyopathy, acidosis and neurologic disease. Some defects are treatable, such as primary coenzyme Q deficiencies or riboflavin transport defects in specific settings. Rapid genomic diagnosis in intensive care can therefore change treatment, prognosis and reproductive risk.

Variants in DNAJC19 cause dilated cardiomyopathy with ataxia syndrome, described especially in certain populations, whereas OPA1 and MFN2 link mitochondrial dynamics, neuropathy and sometimes cardiac involvement. POLG defects may be dominated by epilepsy and liver disease rather than cardiomyopathy. The gene-organ signature guides surveillance and medication choices without assuming that every mitochondrial protein carries the same cardiac risk.

Maternally inherited diabetes and deafness associated with m.3243A>G may be diagnosed in an adult with atypical diabetes and deafness before hypertrophy emerges. Glycemic control should avoid drugs unsuitable for the individual risk of acidosis and take renal function and weight into account; not every patient requires insulin at the same time. The diabetes-hearing-heart triad is a diagnostic gateway that is often missed when specialists view organs separately.

Pediatric age and intensive care

In a newborn with cardiomyopathy, acidosis, hypotonia or malformations, samples for lactate, pyruvate, ammonia, acylcarnitines, organic acids and DNA are collected during stabilization. Echocardiography, ECG, brain, liver and kidney assessment define the phenotype; rapid trio genome sequencing can shorten weeks of uncertainty. Parallel critical diagnosis avoids empirical biopsies and identifies treatable defects or prognoses that modify support and counseling.

In intensive care, inotropes and ventilation increase or reduce energy consumption and are titrated to perfusion, lactate and function. Rising lactate may result from the defect, shock, beta-agonists or all of them together; chasing it with excessive fluids worsens a fragile heart. Hemodynamic interpretation of lactate distinguishes metabolic production from hypoperfusion and prevents resuscitation driven by an isolated number.

Enteral or parenteral nutrition is introduced while avoiding fasting but controlling the ability to oxidize fats and glucose according to the defect. Excess calories increase carbon dioxide production and steatosis; restriction increases catabolism. A metabolic dietitian and intensivist define substrates, electrolytes and micronutrients. Energy nutrition is a physiologic titration, not the automatic use of a high-glucose solution.

Decisions about ECMO, mechanical support and transplantation in newborns must balance reversibility of the crisis against neurologic or multisystem severity. A rapid genotype informs but does not replace values and uncertainty; some phenotypes described as lethal show variability. Proportionality of support requires multidisciplinary updates and honest communication with the family, without using a molecular result as an automatic verdict.

Metabolic differential diagnosis

Fatty-acid oxidation and carnitine transport defects can cause cardiomyopathy and arrhythmias during fasting, but they have characteristic acylcarnitine profiles and specific treatments; primary carnitine deficiency is treatable. Organic acidemias, urea-cycle disorders and sepsis may mimic a mitochondrial crisis. The treatable differential diagnosis comes before the broad label of cytopathy, especially when time is critical.

Pompe disease and other glycogen storage diseases cause hypertrophy with hypotonia, Fabry disease an adult phenotype with low T1, Danon disease pre-excitation and myopathy, whereas sarcomeric disease may coexist with common diabetes. Maternal inheritance is suggestive, but small families, de novo disease and nuclear genes make it nonessential. Phenotypic comparison uses compartment, biochemistry and pedigree to avoid turning every multisystem cardiomyopathy into a mitochondrial disorder.

Endocrine disorders such as hyperthyroidism, acromegaly and diabetes may raise lactate or remodel the heart; drugs and alcohol cause acquired mitochondrial toxicity without constituting a primary genetic disease. The label should describe the cause, not merely altered organelles observed in an end-stage heart. Etiologic specificity separates secondary mitochondrial dysfunction, which is common in heart failure, from rare inherited cytopathy.

Measuring progression

Weight, strength, respiratory function, hearing, glycemia, renal function, neurologic status and cardiac status are measured with reproducible tools. Blood heteroplasmy is not a universal serial biomarker and may change without reflecting the heart. Lactate is too variable to serve as the sole endpoint. The clinical trajectory uses events, function and imaging and reserves molecular markers for questions for which they have been validated.

Cardiac risk does not necessarily increase in parallel with neurologic disease. A cognitively stable patient may develop heart block, whereas a person with severe disability may preserve ventricular function. Separate plans for conduction, myocardium and thromboembolism are brought together at the multidisciplinary visit. Organ discordance means that cardiac screening should not be shortened because another domain appears to dominate the disease.

Emerging biomarkers such as GDF-15 and FGF-21 may support the presence of mitochondrial myopathy but are nonspecific and are affected by renal, hepatic and other diseases. They do not replace genetic testing or independently define response. Biomarker validation requires appropriate populations and laboratory thresholds, preventing a research test from becoming an isolated commercial diagnosis.

Multisystem red flags

Maternal inheritance of diabetes, hearing loss, short stature, cardiomyopathy or stroke is a powerful clue. Ptosis, ophthalmoplegia, neuropathy, ataxia, epilepsy, migraine, exercise intolerance and weakness increase the likelihood; retinopathy, tubulopathy, endocrine dysfunction and gastrointestinal disorders complete the spectrum. No patient needs to have all of them. Incomplete multisystem involvement is the rule, not an argument against the diagnosis.

Lactate and the lactate-to-pyruvate ratio may be abnormal, but difficult sampling, tourniquet use, exercise, shock and seizures raise them; between crises they may be normal. Alanine, organic acids, acylcarnitines and CK are requested according to the clinical setting. A mitochondrial diagnosis does not arise from a moderately high lactate value and is not excluded by a normal one. Contextualized biochemistry guides gene selection and recognizes a crisis without becoming a binary test.

Cardiologic assessment

ECG, echocardiography and rhythm monitoring are recommended at diagnosis even in the absence of symptoms. Echocardiography assesses wall thickness, function, noncompaction, atria and the right ventricle; strain may detect early dysfunction. Holter or longer monitoring looks for pauses, block, ectopy and tachyarrhythmias. The cardiac baseline makes it possible to distinguish chronic variation from metabolic decompensation.

CMR defines volumes and LGE and may show edema or abnormal mapping, but there is no universal mitochondrial signature. Sedation, devices, renal function and the ability to remain supine affect the examination. Cardiopulmonary exercise testing measures central and peripheral limitation, but is used cautiously in rhabdomyolysis or instability. Proportionate multimodality assessment answers a clinical question while avoiding unnecessary diagnostic stress.

Follow-up intervals depend on age, gene and findings; children with cardiomyopathy and people with Kearns-Sayre require closer surveillance than a stable adult without cardiac involvement. New syncope, palpitations, dyspnea or crises require earlier reassessment. Function may change with endocrine or renal therapies and with pregnancy. Adaptive surveillance is safer than an identical schedule for hundreds of genotypes.

Genetic diagnosis and tissue selection

The modern pathway often analyzes mtDNA and nuclear genes simultaneously by panels, exome or genome sequencing, with assessment of heteroplasmy and deletion detection. Blood is accessible but may have low sensitivity for some variants, particularly m.3243A>G in adults; urinary sediment, buccal mucosa or muscle may be more informative. Sample selection depends on the suspected defect and should be agreed with an experienced laboratory.

An mtDNA variant is interpreted using heteroplasmy, tissue, frequency, maternal segregation and functional evidence. Mendelian criteria are applied to nuclear genes, but biallelic variants, copy-number changes and splicing defects may require additional analyses. Negative sequencing does not exclude every defect; muscle biopsy with histology, respiratory-chain biochemistry and mtDNA analysis remains useful in selected cases. Integrated diagnosis avoids both early invasiveness and abandoning the evaluation after a negative exome.

Ragged-red fibers, COX-negative fibers and mitochondrial accumulation support a disorder, but vary with age and are not specific to every genotype. Cardiac biopsy is rarely the first choice and is reserved for differential diagnoses in which the result would change care. Pathologist, geneticist and biochemist should plan fixation and freezing before sampling. Pre-analytical quality determines whether a rare specimen yields information or merely unusable tissue.

Cardiac treatment and specific therapies

Heart failure is treated according to guidelines with drugs adapted to blood pressure, renal function, conduction and metabolic risk. There is no evidence that standard therapy is ineffective simply because the etiology is mitochondrial; however, treatment should be titrated during stability and reassessed after crises. Diuretics control congestion, while catabolism and excessive dehydration should be avoided. Complete cardiologic therapy should not be replaced by supplements.

A pacemaker is indicated for heart block and, in Kearns-Sayre, is considered preventively with particular attention. ICD use follows secondary-prevention indications and individual risk; resynchronization may be useful when appropriate criteria are met, but weakness and extracardiac prognosis enter the decision. Anticoagulation treats atrial fibrillation and thrombus when indicated. The device strategy distinguishes protection from heart block, tachyarrhythmias and dyssynchrony.

Coenzyme Q10 is indicated in primary coenzyme Q biosynthesis defects and riboflavin in specific responsive disorders; arginine is used in protocols for MELAS stroke-like episodes, with nonuniform evidence. Idebenone has specific indications in some jurisdictions for optic neuropathy, not as a general treatment for cardiomyopathy. So-called mitochondrial cocktails have limited evidence and possible interactions. Genotype-specific therapy separates a proven deficiency from empiricism.

Moderate aerobic and resistance exercise may improve capacity and mitochondrial function without necessarily increasing heteroplasmy, when prescribed and progressive. Severe cardiomyopathy, arrhythmias, rhabdomyolysis and crises require individual restrictions. Rehabilitation, ventilation, nutrition, hearing, diabetes and epilepsy indirectly affect the heart. Systemic care reduces the energy cost of other dysfunctions.

Heart transplantation is possible when the heart limits prognosis and neurologic, respiratory and muscular involvement permits rehabilitation and survival. Selection should neither automatically exclude a mitochondrial diagnosis nor ignore the possibility that surgical stress will reveal involvement of other organs. Genotype, rate of progression and independence inform the decision. Individual candidacy replaces both rejection based on the label and optimism focused only on the heart.

After transplantation, the donor heart does not carry the recipient's mtDNA variant, but medications, infections and progression of neuromuscular disease may complicate the course. A nuclear defect is present in the recipient's cells but not in the graft; this is not an infiltrative disease that automatically recurs. The biology of transplantation must be explained correctly to balance systemic risk against the possibility of durable benefit.

Palliative care may accompany active treatments when crises, neurologic disease and heart failure produce a high burden. Control of dyspnea, pain, secretions and anxiety does not mean abandoning ventilation, devices or metabolic therapy compatible with the goals of care. Concurrent palliation improves quality and decision-making and is introduced before the terminal phase in an unpredictable disease.

Metabolic crises, medications and anesthesia

Fever, vomiting, fasting, surgery and labor increase demand or reduce substrates and may precipitate acidosis, rhabdomyolysis, arrhythmias and heart failure. An emergency plan limits fasting, provides fluids and glucose when appropriate, and monitors lactate, electrolytes, CK, liver, kidney, ECG and function. Volume and glucose must be adapted to the heart and the defect, not administered automatically. Catabolism prevention requires metabolic and intensive-care coordination.

Valproate may cause devastating liver failure in POLG defects and should be avoided when that suspicion is relevant; linezolid, aminoglycosides in specific mtDNA variants and other drugs require caution. Prolonged propofol infusion increases the risk of propofol infusion syndrome, whereas a brief bolus is not equivalent to continuous infusion. Anesthesia is not prohibited, but requires cardiac, respiratory, glycemic and thermal assessment. Targeted pharmacovigilance avoids absolute lists without context.

Family, reproduction and prognosis

Pregnancy in an affected woman increases energy demands and may worsen diabetes, cardiac disease or weakness. Preconception assessment includes ECG, echocardiography, rhythm, respiratory function, kidney function and medications; delivery and the postpartum period are planned with anesthesia and a metabolic center. Maternal reserve is considered separately from the risk of mtDNA transmission, which requires dedicated reproductive counseling.

Preimplantation genetic testing for mtDNA variants may reduce but not eliminate risk, because sampling and heteroplasmy drift complicate prediction. Oocyte donation eliminates transmission of maternal mtDNA, whereas mitochondrial replacement techniques are regulated in only a few countries. Reproductive communication must distinguish technical availability, legality, residual risk and the effect on nuclear genetic identity.

A woman with an mtDNA variant may transmit it to all her children, but the oocyte bottleneck makes heteroplasmy and severity unpredictable; a man does not transmit his mtDNA. Dominant, recessive or X-linked risks apply to nuclear genes. Prenatal diagnosis for mtDNA is complex, and options include preimplantation testing and, where regulated, donation or mitochondrial replacement. Specialist reproductive counseling must make predictive limitations explicit.

At-risk relatives receive targeted testing and organ assessment, but low heteroplasmy in blood does not guarantee absence in other tissues. Surveillance should take the gene and family into account, avoiding endless testing in relatives who have been genetically excluded. In children, growth and development may rapidly modify the phenotype. An informed cascade links the molecular result to physiology and is not limited to a positive report.

Prognosis ranges from rapidly progressive infantile cardiomyopathy to normal life expectancy with mild manifestations. Ventricular dysfunction, heart block, arrhythmias, respiratory failure and severe neurologic disease worsen outcome; some forms respond to specific therapies or selected transplantation. A syndromic average does not predict an individual with different heteroplasmy. Multidimensional prognosis is updated throughout life and must integrate cardiac risk, independence and the person's goals.

An emergency card should report the variant, risk of heart block, device, genotype-specific drugs to avoid, ventilation and contacts. The generic phrase mitochondrial disease does not tell the physician whether the problem is POLG, an mtDNA deletion or a coenzyme Q defect. Operational information reduces errors in settings where the patient cannot reconstruct a long multispecialty history.

Coordination must leave room for personal goals, school, work and invisible fatigue. The number of tests is proportionate to their ability to change decisions, avoiding surveillance that consumes the energy it is intended to protect. Function-centered medicine complements genomic precision and recognizes that a good outcome is not defined solely by ventricular stability.

Periodic variant review is necessary because new genes, techniques and functional data may resolve cases that remained uncertain. Iterative diagnosis does not mean repeating tests without rationale, but reopening the case when new knowledge can change surveillance, treatment or familial risk.